EP0944394A4 - Behandlung einer hiv-infektion durch beeinträchtigung der cyclophilinrezeptor-aktivität innerhalb der wirtszelle - Google Patents

Behandlung einer hiv-infektion durch beeinträchtigung der cyclophilinrezeptor-aktivität innerhalb der wirtszelle

Info

Publication number
EP0944394A4
EP0944394A4 EP97917517A EP97917517A EP0944394A4 EP 0944394 A4 EP0944394 A4 EP 0944394A4 EP 97917517 A EP97917517 A EP 97917517A EP 97917517 A EP97917517 A EP 97917517A EP 0944394 A4 EP0944394 A4 EP 0944394A4
Authority
EP
European Patent Office
Prior art keywords
hiv
interfering
infection
treatment
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97917517A
Other languages
English (en)
French (fr)
Other versions
EP0944394A1 (de
Inventor
Michael Bukrinsky
Barbara A Sherry
Peter C Ulrich
Anthony Cerami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Original Assignee
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/615,933 external-priority patent/US5840305A/en
Application filed by Picower Institute for Medical Research filed Critical Picower Institute for Medical Research
Publication of EP0944394A1 publication Critical patent/EP0944394A1/de
Publication of EP0944394A4 publication Critical patent/EP0944394A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP97917517A 1996-03-12 1997-03-12 Behandlung einer hiv-infektion durch beeinträchtigung der cyclophilinrezeptor-aktivität innerhalb der wirtszelle Withdrawn EP0944394A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1318596P 1996-03-12 1996-03-12
US613185P 1996-03-12
US08/615,933 US5840305A (en) 1996-03-14 1996-03-14 Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
US615933 1996-03-14
PCT/US1997/003819 WO1997033604A1 (en) 1996-03-12 1997-03-12 Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity

Publications (2)

Publication Number Publication Date
EP0944394A1 EP0944394A1 (de) 1999-09-29
EP0944394A4 true EP0944394A4 (de) 2003-05-14

Family

ID=26684543

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917517A Withdrawn EP0944394A4 (de) 1996-03-12 1997-03-12 Behandlung einer hiv-infektion durch beeinträchtigung der cyclophilinrezeptor-aktivität innerhalb der wirtszelle

Country Status (5)

Country Link
EP (1) EP0944394A4 (de)
JP (1) JP2000510097A (de)
AU (1) AU723905B2 (de)
CA (1) CA2248192A1 (de)
WO (1) WO1997033604A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326040T3 (es) 2001-10-19 2009-09-29 Isotechnika Inc. Sintesis de analogos de ciclosporina.
DE20220744U1 (de) * 2001-10-25 2004-05-13 Viromics Gmbh Mittel zur Hemmung von Lentiviren
US7108988B2 (en) 2001-11-02 2006-09-19 The J. David Gladstone Institutes Methods of identifying agents for inhibiting lentivirus replication
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
EP3840769B1 (de) * 2018-08-22 2024-07-24 Bacainn Biotherapeutics, Ltd. Cyclosporinzusammensetzungen und verfahren zur verwendung

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (de) * 1990-11-02 1992-05-06 Sandoz Ltd. Zyklosporine
WO1993023081A1 (en) * 1992-05-15 1993-11-25 The Rockefeller University Methods and agents for modulating immune response, and uses thereof
WO1995007468A1 (en) * 1993-09-08 1995-03-16 Sandoz Ltd. Assay kit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (de) * 1990-11-02 1992-05-06 Sandoz Ltd. Zyklosporine
WO1993023081A1 (en) * 1992-05-15 1993-11-25 The Rockefeller University Methods and agents for modulating immune response, and uses thereof
WO1995007468A1 (en) * 1993-09-08 1995-03-16 Sandoz Ltd. Assay kit

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALLAIN F ET AL: "Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 178, no. 1, 13 January 1995 (1995-01-13), pages 113 - 120, XP004021130, ISSN: 0022-1759 *
BILLICH A ET AL: "MODE OF ACTION OF SDZ NIM 811, A NONIMMUNOSUPPRESSIVE CYCLOSPORIN A ANALOG WITH ACTIVITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPE 1: INTERFERENCE WITH HIV PROTEIN-CYCLOPHILIN A INTERACTIONS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 4, 1 April 1995 (1995-04-01), pages 2451 - 2461, XP002022423, ISSN: 0022-538X *
ROYDON PRICE E ET AL: "CYCLOPHILIN B TRAFFICKING THROUGH THE SECRETORY PATHWAY IS ALTERED BY BINDING OF CYCLOSPORIN A", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 91, April 1994 (1994-04-01), pages 3931 - 3935, XP002931337, ISSN: 0027-8424 *
See also references of WO9733604A1 *

Also Published As

Publication number Publication date
WO1997033604A1 (en) 1997-09-18
EP0944394A1 (de) 1999-09-29
AU723905B2 (en) 2000-09-07
AU2581197A (en) 1997-10-01
JP2000510097A (ja) 2000-08-08
CA2248192A1 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
EP0810864A4 (de) 2,6-diaryl pyridazinone mit immunosuppressiver wirkung
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
HUP9702242A3 (en) Inozitol-glykanes of inzulin-like activity
GB9616282D0 (en) Enzyme activity enhancement
EP0858456A4 (de) Triterpen-derivate mit immunosuppressiver aktivität
ZA964880B (en) Pain cell line
IL128517A (en) Dihydropyrones with improved antiviral activity
HU9600272D0 (en) 10-amino-aliphatic-dibenzo-[b,f]oxepines of antineurodegenerative activity
EP0944394A4 (de) Behandlung einer hiv-infektion durch beeinträchtigung der cyclophilinrezeptor-aktivität innerhalb der wirtszelle
EP0858332A4 (de) Triterpenderivate mit immunosuppressiver wirkung
ZA965191B (en) Cell treatment
IL129576A0 (en) Mouse cardiac muscle cell line hl-1
EP0948254A4 (de) Zelltest zur bestätigung enzymatischer aktivität
AU5926998A (en) Treatment of diabetes with synthetic beta cells
PL331855A1 (en) Biological reactor
AU8999298A (en) Protein having activity of activiting nerve cell functions
EP1107774A4 (de) RAMP2a: REZEPTOR-AKTIVITÄT MODIFIZIERENDES PROTEIN-2a
AUPN190695A0 (en) Compounds with steroid-like activity
AUPN889996A0 (en) Compounds with steroid-like activity
GB9603850D0 (en) Triterpene derivatives with immunosuppressant activity
GB9626239D0 (en) Triterpene derivatives with immunosuppressant activity
GB9626228D0 (en) Triterpene derivatives with immunosuppressant activity
GB9605161D0 (en) Triterpene derivatives with immunosuppressant activity
GB9605159D0 (en) Triterpene derivatives with immunosuppressant activity
GB9605156D0 (en) Triterpene derivatives with immunosuppressant activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030402

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39:00 K

Ipc: 7A 61K 39/39 K

Ipc: 7A 61K 38:13 J

Ipc: 7A 61K 47/48 J

Ipc: 7A 61K 47/48 B

Ipc: 7C 12N 9/90 B

Ipc: 7A 61K 39/39 B

Ipc: 7A 61K 39/395 B

Ipc: 7A 61K 38/13 A

17Q First examination report despatched

Effective date: 20031023

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050719